SCHEMBL4239889

SCHEMBL4239889

CC(C)(C)OC(=O)N1CCC(C(O)c2ccc(Br)cc2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.52
NPC1 O15118 1/20 0.52
MAPT P10636 1/20 0.52
MAPK1 P28482 1/20 0.52
HTT P42858 1/20 0.52
RAB9A P51151 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
EED O75530 1/20 0.51
RBBP4 Q09028 1/20 0.51
SUZ12 Q15022 1/20 0.51
EZH2 Q15910 1/20 0.51
AEBP2 Q6ZN18 1/20 0.51
DPP4 P27487 1/20 0.48
FPR2 P25090 3/20 0.47
CCR5 P51681 1/20 0.47
GPR119 Q8TDV5 7/20 0.47
PTPN2 P17706 1/20 0.46
PTPN1 P18031 1/20 0.46
PTPN6 P29350 1/20 0.46
FPR3 P25089 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4240647 1.00 ALDH1A1 (0.52) ALDH1A1NPC1MAPTMAPK1HTT
SCHEMBL4244525 1.00 ALDH1A1 (0.52) ALDH1A1NPC1MAPTMAPK1HTT
SCHEMBL26187622 0.93 NPC1 (0.47) ALDH1A1NPC1MAPTMAPK1HTT
SCHEMBL13897657 0.89 DPP4 (0.53) ALDH1A1NPC1MAPTMAPK1HTT
SCHEMBL18321535 0.87 ALDH1A1 (0.55) ALDH1A1NPC1MAPTMAPK1HTT
SCHEMBL2520399 0.87 ALDH1A1 (0.55) ALDH1A1NPC1MAPTMAPK1HTT
SCHEMBL4393991 0.87 MMP13 (0.55) ALDH1A1NPC1MAPTMAPK1HTT
SCHEMBL24357345 0.87 RORC (0.46) ALDH1A1NPC1MAPTMAPK1HTT
SCHEMBL22558670 0.87 GPR119 (0.59) ALDH1A1NPC1MAPTMAPK1HTT
SCHEMBL1405370 0.87 GPR119 (0.59) ALDH1A1NPC1MAPTMAPK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12441702-B2 Substituted 4-benzyl and 4-benzoyl piperidine derivates CEPHALON LLC (US) 2025-10-14 US disclosed
US-20240166625-A1 Substituted 4-Benzyl And 4-Benzoyl Piperidine Derivates CEPHALON LLC 2024-05-23 US disclosed
US-11878966-B2 Substituted 4-benzyl and 4-benzoyl piperidine derivates 89BIO LTD (IL) 2024-01-23 US disclosed
US-20220081411-A1 Substituted 4-Benzyl And 4-Benzoyl Piperidine Derivates CEPHALON LLC 2022-03-17 US disclosed
US-10919875-B2 Substituted 4-benzyl and 4-benzoyl piperidine derivatives 89BIO LTD (IL) 2021-02-16 US disclosed
EP-3310773-B1 SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES 89BIO LTD (IL) 2020-12-02 EP disclosed
US-20200031797-A1 SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES CEPHALON LLC 2020-01-30 US disclosed
EP-3310773-A1 SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES Cephalon, Inc. (US) 2018-04-25 EP disclosed
WO-2016205590-A1 SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES CEPHALON, INC. (US) 2016-12-22 WO disclosed
US-7511146-B2 2-substituted benzimidazole piperidines analogs as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders SCHERING CORPORATION (US) 2009-03-31 US disclosed
US-7511146-B2 2-substituted benzimidazole piperidines analogs as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders SCHERING CORPORATION (US) 2009-03-31 US disclosed
US-7491735-B2 Chemokine receptor binding compounds GENZYME CORPORATION (US) 2009-02-17 US disclosed
EP-1708703-A4 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED INC (CA) 2008-04-09 EP disclosed
EP-1708703-A2 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED INC. (CA) 2006-10-11 EP disclosed
US-20050277670-A1 Chemokine receptor binding compounds ANORMED INC. 2005-12-15 US disclosed
WO-2005059107-A2 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED INC. (CA) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12441702-B2 Substituted 4-benzyl and 4-benzoyl piperidine derivates FASN, CES1, FADS2 ALDH1A1 106/4885NPC1 217/4885MAPT 3856/4885
US-20240166625-A1 Substituted 4-Benzyl And 4-Benzoyl Piperidine Derivates FASN, CES1, FADS2 ALDH1A1 106/4885NPC1 217/4885MAPT 3856/4885
US-20200031797-A1 SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES FASN, FADS1, ASS1 ALDH1A1 170/4885NPC1 106/4885MAPT 3566/4885
US-10919875-B2 Substituted 4-benzyl and 4-benzoyl piperidine derivatives FASN, CES1, FADS2 ALDH1A1 149/4885NPC1 222/4885MAPT 4144/4885
US-20220081411-A1 Substituted 4-Benzyl And 4-Benzoyl Piperidine Derivates FASN, CES1, FADS2 ALDH1A1 106/4885NPC1 217/4885MAPT 3856/4885
US-20050277670-A1 Chemokine receptor binding compounds CCR5, CXCR3, CCL5 ALDH1A1 3358/4885NPC1 542/4885MAPT 3843/4885
US-11878966-B2 Substituted 4-benzyl and 4-benzoyl piperidine derivates FASN, CES1, FADS2 ALDH1A1 106/4885NPC1 217/4885MAPT 3856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.